Recursion Pharmaceuticals, Inc.

RXRX

US75629V1044

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:53:15 2026-01-22 EST			5-day change	1st Jan Change
5.125 ^USD	+11.17%		+7.33%	+21.76%

01-13	Recursion Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
01-13	Illumina unveils dataset to speed up AI-powered drug discovery	RE

Recursion to lay off 20% of workforce amid biotech funding woes

Published on 06/10/2025 at 07:46 am EDT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Recursion Pharmaceuticals, Inc.

01-13	Recursion Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
01-13	Illumina unveils dataset to speed up AI-powered drug discovery	RE
01-08	Recursion Pharmaceuticals Insider Sold Shares Worth $959,200, According to a Recent SEC Filing	MT
12-30	XOMA Royalty Amends Takeda Deal, Expects Royalties Tied to Broader Asset Portfolio	MT
12-30	XOMA Royalty Corporation Amends Its Collaboration with Takeda Through Strategic Royalty Share Transaction	CI
12-17	Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade	MT
12-17	Recursion Pharmaceuticals rises 13.1% after JP Morgan raises co to 'overweight' from 'neutral'	RE
12-17	JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10	MT
12-08	Recursion Says REC-4881 Reduces Polyps in Phase 1b/2 Familial Adenomatous Polyposis Trial	MT
12-08	Recursion Pharmaceuticals, Inc. - Special Call
12-08	Why the Fed's Next Move Matters More Than Markets Admit
12-08	Recursion's Tupelo trial phase 1b/2 results show polyp burden reductions in FAP at 25 weeks	RE
12-08	Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial	RE
12-08	Recursion Pharmaceuticals, Inc. announces Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis at 25 Weeks	CI
12-04	Recursion Pharmaceuticals Insider Sold Shares Worth $961,400, According to a Recent SEC Filing	MT
12-01	Recursion to host webinar on Tupelo Phase 1b/2 data for REC-4881 in familial adenomatous polyposis on Dec. 8	RE
11-21	Recursion Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 10:30 AM
11-17	Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says	MT
11-17	Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5 From $4.80, Keeps Equalweight Rating	MT
11-05	Recursion Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 05, 2025
11-05	Recursion Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective January 1, 2026	CI
11-05	Recursion Pharmaceuticals, Inc. Announces Management Changes, Effective January 1, 2026	CI
11-05	Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	Recursion Pharmaceuticals Names Najat Khan as Chief Executive and President	MT
11-05	Recursion Pharmaceuticals Q3 Loss Widens, Revenue Falls	MT

Chart Recursion Pharmaceuticals, Inc.

Duration

Period

RXRX: Dynamic Chart

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Employees

800

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company